Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Smolle, MA; van Praag, VM; Posch, F; Bergovec, M; Leitner, L; Friesenbichler, J; Heregger, R; Riedl, JM; Pichler, M; Gerger, A; Szkandera, J; Stöger, H; Smolle-Jüttner, FM; Liegl-Atzwanger, B; Fiocco, M; van de Sande, MA; Leithner, A.
Surgery for metachronous metastasis of soft tissue sarcoma - A magnitude of benefit analysis using propensity score methods.
Eur J Surg Oncol. 2019; 45(2):242-248
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Bergovec Marko
Friesenbichler Jörg
Gerger Armin
Leithner Andreas
Leitner Lukas
Liegl-Atzwanger Bernadette
Pichler Martin
Posch Florian
Riedl Jakob
Smolle Maria
Smolle-Juettner Freyja-Maria
Stoeger Herbert
Szkandera Joanna
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
Metastasectomy is hypothesised to improve OS in metastatic STS, but evidence in favour of this approach derives from non-controlled single-arm cohorts affected by selection bias. The objective was to quantify the effect of metastasectomy vs. non-surgical management on overall survival (OS) in patients with metachronous metastases from extremity- and trunk soft tissue sarcoma (STS). From a population of 1578 STS patients, 135 patients who underwent surgery for localised STS at two European centres between 1998 and 2015 and developed metachronous STS metastases were included. Propensity score analyses with inverse-probability-of-treatment-weights (IPTW) and landmark analyses were performed to control for selection and immortal time bias, respectively. OS was significantly longer in the 68 patients undergoing metastasectomy than in the 67 patients who were treated non-invasively for their metastasis (10-year OS: 23% vs. 4%; hazard ratio (HR) = 0.34, 95% CI: 0.22-0.53, p < 0.0001). This association prevailed after IPTW-weighting of the data to control for the higher prevalence of favourable prognostic factors in the surgery group (adjusted 10-year OS: 17% vs. 3%, log-rank p < 0.0001; HR = 0.33, 95% CI: 0.20-0.52, p < 0.0001). Five-year OS estimates were 27.8% in patients who had and 14.5% in patients who had not undergone metastasectomy within the first 3 months after diagnosis of a metastasis (p < 0.0001). In this observational bi-centre study, metastasectomy was associated with prolonged survival in patients with metachronous STS metastases. In the absence of randomized studies, our results indicate that metastasectomy should be considered as an important treatment option for metachronous STS metastases. Copyright © 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Find related publications in this database (Keywords)
Soft tissue sarcoma
Metastasis
Overall-survival
Metastasectomy
© Med Uni Graz Impressum